Heart Failure: Evolving Treatment Choices and New Guidance

The number of Americans with HF is increasing. Despite the many agents approved to manage HF, the prognosis has only improved somewhat, with a 5-year mortality rate after initial hospitalization of 42.3%. Guidelines are frequently updated, with the most recent ACC consensus on optimizing treatment published in 2022. Some agents to treat HFrEF are relatively new and several agents are in late-stage development. For patients with HFpEF there are currently no approved therapies although there are agents in phase 3 clinical trials.

Share

Program Content

Activities

  • Heart Failure
    Heart Failure: Evolving Treatment Choices and New Guidance
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 24, 2022

    Expires: October 23, 2023

Faculty

cover img faculity

John Ryan, MD, MB, BCH, BAO

Professor of Medicine
Division of Cardiovascular Medicine
University of Utah
Salt Lake City, Utah

cover img faculity

Muthiah Vaduganathan, MD, MPH

Co-Director, Center for Cardiometabolic Implementation Science
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA

Provided by

ProCE Banner
ProCE Banner

Jointly provided by PCME and Rockpointe.

Supporters

This program is supported by an educational grant from Merck & Co, Inc.

Merck & Co., Inc.